99 related articles for article (PubMed ID: 17380211)
1. Lumiracoxib.
Buvanendran A; Barkin R
Drugs Today (Barc); 2007 Mar; 43(3):137-47. PubMed ID: 17380211
[TBL] [Abstract][Full Text] [Related]
2. Clinical pharmacology of lumiracoxib: a selective cyclo-oxygenase-2 inhibitor.
Rordorf CM; Choi L; Marshall P; Mangold JB
Clin Pharmacokinet; 2005; 44(12):1247-66. PubMed ID: 16372823
[TBL] [Abstract][Full Text] [Related]
3. Clinical pharmacology of lumiracoxib, a second-generation cyclooxygenase 2 selective inhibitor.
Bannwarth B; Berenbaum F
Expert Opin Investig Drugs; 2005 Apr; 14(4):521-33. PubMed ID: 15882125
[TBL] [Abstract][Full Text] [Related]
4. Lumiracoxib in the management of osteoarthritis and acute pain.
Bannwarth B; Bérenbaum F
Expert Opin Pharmacother; 2007 Jul; 8(10):1551-64. PubMed ID: 17661736
[TBL] [Abstract][Full Text] [Related]
5. Lumiracoxib.
Lyseng-Williamson KA; Curran MP
Drugs; 2004; 64(19):2237-46; discussion 2247-8. PubMed ID: 15456339
[TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetics of lumiracoxib in plasma and synovial fluid.
Scott G; Rordorf C; Reynolds C; Kalbag J; Looby M; Milosavljev S; Weaver M; Huff JP; Ruff DA
Clin Pharmacokinet; 2004; 43(7):467-78. PubMed ID: 15139795
[TBL] [Abstract][Full Text] [Related]
7. Lumiracoxib in the treatment of osteoarthritis, rheumatoid arthritis and acute postoperative dental pain: results of three dose-response studies.
Schnitzer TJ; Gitton X; Jayawardene S; Sloan VS
Curr Med Res Opin; 2005 Jan; 21(1):151-61. PubMed ID: 15881487
[TBL] [Abstract][Full Text] [Related]
8. Preclinical pharmacology of lumiracoxib: a novel selective inhibitor of cyclooxygenase-2.
Esser R; Berry C; Du Z; Dawson J; Fox A; Fujimoto RA; Haston W; Kimble EF; Koehler J; Peppard J; Quadros E; Quintavalla J; Toscano K; Urban L; van Duzer J; Zhang X; Zhou S; Marshall PJ
Br J Pharmacol; 2005 Feb; 144(4):538-50. PubMed ID: 15655513
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and tolerability of lumiracoxib in the treatment of osteoarthritis of the knee: a 13-week, randomized, double-blind comparison with celecoxib and placebo.
Sheldon E; Beaulieu A; Paster Z; Dutta D; Yu S; Sloan VS
Clin Ther; 2005 Jan; 27(1):64-77. PubMed ID: 15763607
[TBL] [Abstract][Full Text] [Related]
10. Cardiovascular outcomes in high risk patients with osteoarthritis treated with ibuprofen, naproxen or lumiracoxib.
Farkouh ME; Greenberg JD; Jeger RV; Ramanathan K; Verheugt FW; Chesebro JH; Kirshner H; Hochman JS; Lay CL; Ruland S; Mellein B; Matchaba PT; Fuster V; Abramson SB
Ann Rheum Dis; 2007 Jun; 66(6):764-70. PubMed ID: 17412741
[TBL] [Abstract][Full Text] [Related]
11. Lumiracoxib (Prexige): a new selective COX-2 inhibitor.
Mysler E
Int J Clin Pract; 2004 Jun; 58(6):606-11. PubMed ID: 15311562
[TBL] [Abstract][Full Text] [Related]
12. Comparison of lumiracoxib with naproxen and ibuprofen in the Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET), reduction in ulcer complications: randomised controlled trial.
Schnitzer TJ; Burmester GR; Mysler E; Hochberg MC; Doherty M; Ehrsam E; Gitton X; Krammer G; Mellein B; Matchaba P; Gimona A; Hawkey CJ;
Lancet; 2004 Aug 21-27; 364(9435):665-74. PubMed ID: 15325831
[TBL] [Abstract][Full Text] [Related]
13. Comparison of lumiracoxib with naproxen and ibuprofen in the Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET), cardiovascular outcomes: randomised controlled trial.
Farkouh ME; Kirshner H; Harrington RA; Ruland S; Verheugt FW; Schnitzer TJ; Burmester GR; Mysler E; Hochberg MC; Doherty M; Ehrsam E; Gitton X; Krammer G; Mellein B; Gimona A; Matchaba P; Hawkey CJ; Chesebro JH;
Lancet; 2004 Aug 21-27; 364(9435):675-84. PubMed ID: 15325832
[TBL] [Abstract][Full Text] [Related]
14. Pharmacology and gastrointestinal safety of lumiracoxib, a novel cyclooxygenase-2 selective inhibitor: An integrated study.
Atherton C; Jones J; McKaig B; Bebb J; Cunliffe R; Burdsall J; Brough J; Stevenson D; Bonner J; Rordorf C; Scott G; Branson J; Hawkey CJ
Clin Gastroenterol Hepatol; 2004 Feb; 2(2):113-20. PubMed ID: 15017615
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and tolerability of lumiracoxib versus placebo in patients with osteoarthritis of the hand.
Grifka JK; Zacher J; Brown JP; Seriolo B; Lee A; Moore A; Gimona A
Clin Exp Rheumatol; 2004; 22(5):589-96. PubMed ID: 15485012
[TBL] [Abstract][Full Text] [Related]
16. Clinical pharmacology of selective COX-2 inhibitors.
Capone ML; Tacconelli S; Sciulli MG; Patrignani P
Int J Immunopathol Pharmacol; 2003; 16(2 Suppl):49-58. PubMed ID: 14552704
[TBL] [Abstract][Full Text] [Related]
17. Lumiracoxib is effective in the treatment of osteoarthritis of the knee: a 13 week, randomised, double blind study versus placebo and celecoxib.
Tannenbaum H; Berenbaum F; Reginster JY; Zacher J; Robinson J; Poor G; Bliddal H; Uebelhart D; Adami S; Navarro F; Lee A; Moore A; Gimona A
Ann Rheum Dis; 2004 Nov; 63(11):1419-26. PubMed ID: 15020310
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and tolerability of lumiracoxib 200 mg once daily for treatment of primary dysmenorrhea: results from two randomized controlled trials.
Daniels S; Gitton X; Zhou W; Stricker K; Barton S
J Womens Health (Larchmt); 2008 Apr; 17(3):423-37. PubMed ID: 18373490
[TBL] [Abstract][Full Text] [Related]
19. Similar maximum systemic but not local cyclooxygenase-2 inhibition by 50 mg lumiracoxib and 90 mg etoricoxib: a randomized controlled trial in healthy subjects.
Felden L; Walter C; Angioni C; Schreiber Y; von Hentig N; Ferreiros N; Geisslinger G; Lötsch J
Pharm Res; 2014 Jul; 31(7):1813-22. PubMed ID: 24469906
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and safety of four doses of lumiracoxib versus diclofenac in patients with knee or hip primary osteoarthritis: a phase II, four-week, multicenter, randomized, double-blind, placebo-controlled trial.
Schnitzer TJ; Beier J; Geusens P; Hasler P; Patel SK; Senftleber I; Gitton X; Moore A; Sloan VS; Poór G
Arthritis Rheum; 2004 Aug; 51(4):549-57. PubMed ID: 15334426
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
